Moonshine Research Center Inc — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$636	1
2022	Research	$1,277	1
2021	Research	$263,093	27
2020	Research	$534,922	41
2019	Research	$739,008	44

Breakdown

Who paid Research payments · program years 2019–2025

Pfizer Inc. $1,534,218 104 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $4,358 3 payments
Boehringer Ingelheim International GmbH $214 5 payments
Akebia Therapeutics Inc $146 2 payments

Studies the money was for Research payments · program years 2019–2025

Jak1 Dupilumab Comparator Study $701,966 25 payments
An Openlabel Extension Study to Assess the Longterm Safety and Efficacy of Pf04965842 in Adult Patients With Moderatetosevere Atopic Dermatitis $435,887 35 payments
A Phase 3 Multicenter Longterm Extension Study Investigating the Efficacy and Safety of Abrocitinib With Or Without Topical Medications Administered to Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis $207,674 16 payments
A Phase 3 Randomized Doubleblind Placebocontrolled Multicenter Study Investigating the Efficacy and Safety Ofpf04965842 Coadministered With Background Medicated Topical Therapy in Adolescent Participants 12 to 18 Years of Age With Moderatetosevere Atopic Dermatitis $133,811 21 payments
A Phase 2A Randomized Double Blind Vehicle Controlled Parallel Group Study to Assess the Efficacy Safety Tolerability and Pharmacokinetics of Pf07038124 Ointment for 6 Weeks in Participants With Mild to Moderate Atopic Dermatitis Or Plaque Psoriasis $54,879 7 payments
Proof of concept and DRF in BPD $3,722 7 payments
PoC in Prevention of Relapse $849 1 payment
Akb-6548-Ci-0014 $73 1 payment
Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction of Anemia in Subjects With Non-Dialysis-Dependent Chronic Kidney Disease (Ndd-Ckd) (Pro2tect-Correction) $73 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.